9M India Limited

What 9M India Limited does

9M India Limited is a privately held pharmaceutical contract manufacturer headquartered in Raipur, Chhattisgarh, operating a WHO-GMP certified production facility at Birkoni, Mahasamund. The company manufactures finished dosage forms across thirteen formulation types — tablets, capsules, granules, syrups, suspensions, solutions, ointments, creams, gels, sterile injectables (vials, ampoules, dry powder), eye drops, ear drops and external liquids — covering approximately 995 approved formulations across twelve therapeutic segments including antibiotics, cardiovascular, anti-diabetic, CNS, gastrointestinal, respiratory, dermatology, ophthalmic, pain management, vitamins, paediatrics and anti-infective categories. Annual injectable manufacturing capacity is stated at 177 million units under Grade A/ISO 5 aseptic fill-finish conditions, supported by an in-house analytical QC laboratory (HPLC, UV-Vis, Karl Fischer, LAL endotoxin testing) and cold chain storage.

The business operates on a B2B contract manufacturing model with four primary revenue streams: contract manufacturing under partner product licenses, third-party / PCD franchise manufacturing under the customer's brand name with COA issuance in partner name, institutional and government tender supply (CGHS, ESIC, NHM, state procurement), and international export to distributors in Africa, the Middle East and SAARC regions. Pricing is quote-based and varies by molecule, dosage form, container format and order volume, with a stated minimum order quantity of 100,000 units for domestic injectable supply and case-by-case terms for export orders. Documentation turnaround (COA, COC, stability data, DCGI licenses, WHO-GMP certificates) is contractually committed at 24 hours to support tender bid cycles.

The company serves approximately 195 global clients spanning domestic pharmaceutical brand owners, government healthcare programmes, hospitals, PCD franchise distributors, international distributors and NGOs. Go-to-market combines enterprise field sales (direct engagement with procurement and regulatory affairs teams), a PCD franchise channel model, and event-driven participation in institutional tender programmes. The company began active export operations in 2023 and achieved WHO-GMP certification specifically for sterile injectable manufacturing in 2022; both are reported as material milestones. No external equity funding, M&A, public listing or leadership changes are evidenced in the input materials, and ownership structure beyond the private limited status is not disclosed.

Name

9M India Limited

Legal name

9M India Limited

Website

https://9mindia.in

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

9M India Limited is a privately held, WHO-GMP certified pharmaceutical contract manufacturer in Chhattisgarh, India, producing tablets, capsules, sterile injectables, ophthalmics and topical formulations across 995+ approved formulations for domestic pharma brands, government tenders, PCD franchise partners and international distributors in 15+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIABAH

Generic Finished Dosage Form (FDF) Manufacturing

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

• Pharmaceutical contract manufacturing
• Third-party pharma manufacturing
• WHO-GMP certified manufacturing
• Sterile injectable manufacturing
• Finished dosage formulations

Headquarters

HQ city

Raipur

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Manufacturing pharmaceutical products under partner brand names and product licenses for domestic and international pharma companies. Revenue generated through per-batch manufacturing fees based on volume, formulation complexity, and dosage form type. Single-source accountability from formulation through to final packaging.
2. Third-Party / PCD Franchise Manufacturing: Manufacturing under partner brands with COA issued in partner's product name. Revenue per unit/batch for pharmaceutical companies, PCD franchise distributors, and private label buyers.
3. Institutional and Government Tender Supply: Direct supply to government procurement programmes (CGHS, ESIC, NHM, state tenders) and institutional buyers (hospitals, healthcare institutions). Revenue from bulk supply contracts.
4. International Export: Supply to international distributors in Africa, Middle East, and SAARC regions. Export to 15+ countries with regulatory documentation formatted to destination market requirements.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

9M India Limited is a pharmaceutical contract manufacturer that produces finished dosage form medicines across tablets, capsules, syrups, suspensions, ointments, creams, gels, sterile injectables, and ophthalmic preparations at its WHO-GMP certified facility in Chhattisgarh, India. The company manufactures under partner brand names on a third-party/contract basis and also supplies directly to government institutional tenders and international export markets across 15+ countries. Operations span formulation, in-house quality control, regulatory documentation, and 995+ approved formulations with a 177 million unit annual injectable capacity.

Product overview

9M India Limited is a WHO-GMP certified pharmaceutical contract manufacturing company based in India, offering a comprehensive portfolio of finished dosage form (FDF) manufacturing services across 13 formulation types: Tablets, Capsules, Granules & Powders, Syrups, Suspensions, Solutions, Ointments, Creams, Gels, Injections, Eye Drops, Ear Drops, and External Liquid Dosage. The company operates from WHO-GMP certified facilities in Birkoni, Chhattisgarh, with an annual injectable manufacturing capacity of 177 million units and over 995 approved formulations. Their manufacturing services include Contract Manufacturing, 3rd Party Manufacturing, Institutional Tenders, Generic Medicines, OTC Products, Regulatory Services, and QC & QA. Products span 12 therapeutic segments covering Antibiotics, Pain Management, Cardiovascular, Diabetic Care, CNS/Neurology, Gastrointestinal, Respiratory, Dermatology, Vitamins & Minerals, Ophthalmic, Paediatrics, and Anti Infective categories. The company serves domestic supply, institutional procurement, and international export across 15+ countries with full regulatory documentation support including DCGI approvals and WHO-GMP certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Tablets WHO-GMP certified tablet manufacturing across five tablet types including standard compressed, enteric-coated, extended-release, film-coated, and dispersible tablets, covering therapeutic categories such as antibiotics, cardiovascular, antidiabetics, CNS, analgesics, gastrointestinal, and vitamins. Produced for pharmaceutical brand owners, institutional buyers, and international distributors.
• Capsules Hard gelatin and vegetarian HPMC capsule manufacturing in immediate-release, modified-release, and enteric-coated formats for domestic supply, institutional tenders, and international export.
• Granules and Powders Granule and oral powder manufacturing including dry granules, effervescent granules, and reconstitutable powder formulations produced using wet granulation, dry granulation, and fluid bed granulation technologies.
• Syrups Oral syrup manufacturing covering cough syrups, antibiotic dry syrups, paediatric formulations, and nutritional syrups including sugar-free variants, for domestic supply and international export.
• Suspensions Oral suspension manufacturing across reconstitutable dry suspensions and ready-to-use liquid suspensions for analgesic, antibiotic, antifungal, antacid, and paediatric formulations.
• Pharmaceutical Solutions Homogeneous pharmaceutical solutions across analgesic, anti-infective, CNS, gastrointestinal, respiratory, and nutritional therapeutic categories.
• Ointments Ointment manufacturing for dermatological, analgesic, anti-infective, ophthalmic, and wound care formulations using jacketed planetary mixers, triple roller mills, and vacuum homogenisers.
• Creams Cream manufacturing for dermatological, analgesic, antifungal, wound care, gynecological, and cosmeceutical formulations produced as oil-in-water and water-in-oil emulsions using vacuum homogeniser technology.
• Gels Topical gel manufacturing for dermatological, analgesic, anti-infective, oral and dental, gynecological, and ophthalmic gel formulations produced using aqueous, hydroalcoholic, and carbomer-based gel systems.
• Injections Sterile injectable manufacturing of Small Volume Parenterals (SVP) in liquid vials, glass ampoules, and dry powder injection formats across analgesic, anaesthetic, cardiovascular, gastrointestinal, and anti-inflammatory therapeutic categories, with an annual capacity of 177 million units.
• Eye Drops Sterile ophthalmic manufacturing for antibiotic, anti-inflammatory, antiglaucoma, lubricant, anti-allergic, and immunomodulator eye drops produced in classified cleanroom facilities with aseptic fill-finish.
• Ear Drops Sterile ear drop manufacturing for otic preparations in WHO-GMP certified sterile formats.
• External Liquid Dosage (Lotions) External liquid manufacturing for dermatological solutions and lotions, antiseptic preparations, hair and scalp treatments, mouthwash, and gynecological wash formulations.
• Pharmaceutical Contract Manufacturing Services End-to-end contract manufacturing services for pharmaceutical formulations spanning development through delivery, providing domestic and international partners with WHO-GMP certified production capacity.
• Third-Party Manufacturing Services Third-party pharmaceutical manufacturing enabling partners to produce products under their own brand names with COA issued in the partner product name, complete DCGI documentation, and batch quality assurance from the in-house QC laboratory.
• Institutional Tender Supply Services Supply of WHO-GMP certified pharmaceutical products for government and institutional procurement programmes including CGHS, ESIC, state tenders, and NHM supply, with pre-prepared documentation packages that can be turned around within 24 hours of bid notification.
• Generic Medicines Manufacturing Manufacturing and supply of generic pharmaceutical medicines across multiple therapeutic categories for cost-effective healthcare solutions.
• OTC Pharmaceutical Products Manufacturing Over-the-counter pharmaceutical product manufacturing for consumer health markets including topical analgesics, antiseptic preparations, and nutritional supplements.
• Pharmaceutical Regulatory Services Comprehensive regulatory support including DCGI approvals, WHO-GMP documentation, stability data, product dossiers, and export registration support for international markets.
• Quality Control and Quality Assurance Services In-house QC and QA services through an analytical laboratory covering dissolution, disintegration, hardness, friability, assay, content uniformity, sterility, endotoxin, and particulate matter testing for every batch produced.

Quantifiable outcome

• 177 million units annual capacity with 995+ approved formulations
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Akums Drugs & Pharmaceuticals: India's largest pharmaceutical contract manufacturer offering similar multi-dosage form contract manufacturing services including injectables. Both companies serve domestic pharma brands, PCD franchise partners, and institutional buyers under WHO-GMP frameworks.
• Windlas Healthcare: Indian CDMO focused on solid oral dosage forms (tablets, capsules) for domestic and export markets. Comparable to 9M India's contract manufacturing model for branded generic formulations.
• Concord Biotech: Indian CDMO with fermentation-based API manufacturing and formulation capabilities. Comparable as a contract manufacturer serving regulated and semi-regulated export markets.
• Macleods Pharmaceuticals: Vertically integrated Indian pharma company with significant contract manufacturing operations across formulations including injectables, serving domestic and 100+ export markets.
• Tirupati Medicare: Indian pharmaceutical manufacturer producing generic formulations across multiple dosage forms including injectables, serving contract manufacturing and institutional customers similar to 9M India.
• SMS Pharmaceuticals: Indian pharmaceutical manufacturer with API and formulation manufacturing capabilities serving contract manufacturing customers in domestic and export markets similar to 9M India.
• Granules India: Indian pharmaceutical manufacturer specializing in finished dosage forms (paracetamol, metformin) with significant contract manufacturing operations and export presence similar to 9M India.
• Hikal: Indian CDMO offering API and intermediate manufacturing services with formulation capabilities. Comparable as a contract manufacturer serving global pharma customers with regulated facility standards.

Broad incumbents

• Syngene International: India's largest listed CRO/CDMO offering pharmaceutical contract manufacturing and development services. Comparable as a larger, more diversified peer with broader service portfolio including biologics.
• Cipla: Major Indian pharma incumbent with extensive formulation manufacturing and global export presence. Comparable as a much larger peer operating across similar dosage forms and export markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/9mindia_official
• LinkedInlinkedin.com/company/9m-india-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 9M India Limited